Novo Nordisk Chairman Helge Lund is stepping down and and will be replaced by Lars Rebien Sorensen https://t.co/i3akX3Wlcy ...

格隆汇10月21日｜诺和诺德宣布将召开临时股东大会，以选举董事会新成员。 ...

Core Viewpoint - Novo Nordisk announced that its Chair Helge Lund and six other board members will resign at an extraordinary general meeting scheduled for November 14 [1] Group 1 - The resignation of the Chair and board members indicates potential changes in corporate governance [1] - The timing of the extraordinary general meeting suggests a significant shift in the company's leadership structure [1]

Bagsværd, Denmark, 21 October 2025 – Further to company announcement no. 28 issued today, an Extraordinary General Meeting of Novo Nordisk A/S is called to elect new members to the Board of Directors in accordance with the meeting agenda and proposals included in the enclosed meeting notice. The Extraordinary General Meeting will be held on Friday 14 November 2025 at 14:00 (CET). The Extraordinary General Meeting will be held as a fully electronic general meeting. Accordingly, participation in the meeting w ...

Bagsværd, Denmark, 21 October 2025 - Novo Nordisk today announced that the Board of Directors have decided to convene an Extraordinary General Meeting to elect new members of the Board of Directors of Novo Nordisk. “Following dialogue with the Novo Nordisk Foundation regarding the future composition of the Board of Directors, it has not been possible to reach a common understanding. The Board proposed a renewal focusing on addition of select, new competencies while also maintaining continuity, whereas the B ...

Core Insights - Ozempic has gained significant popularity, benefiting its manufacturer, Novo Nordisk A/S [1] Company Summary - Novo Nordisk A/S is experiencing a surge in demand for Ozempic, which has become a notable product in the pharmaceutical market [1]

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Dive Brief: Novo Nordisk’s largest investor said Tuesday it wants to replace more than half of the drugmaker’s board, calling an extraordinary general meeting of shareholders in November to install a handpicked slate of candidates. The election of new candidates is necessary because the current board was “too slow in recognizing” changes in the obesity drug ...

Novo Nordisk, which lobbied to win Medicaid reimbursement for its obesity drug Wegovy, is fighting to keep that coverage as some U.S. states struggle with the treatment's costs, according to state doc... ...

Core Insights - "Buying the dip" can be risky, especially in defensive sectors like healthcare, where stocks may continue to decline for valid reasons [1] Group 1: Moderna - Moderna transitioned from a biotech start-up to a profitable drug company in 2021 and 2022 due to high demand for its COVID-19 vaccine, Spikevax, generating billions in revenue [2] - Demand for COVID-19 vaccines has significantly decreased, leading to a sharp decline in revenue, with last quarter's total sales at just $142 million [3] - Share prices have fallen approximately 35% year-to-date and around 95% from all-time highs in 2021, with potential for further declines unless positive news is announced in the upcoming earnings report on Nov. 6 [4] Group 2: Novo Nordisk - Novo Nordisk, once a leader in GLP-1 therapies, faces increased competition from companies like Eli Lilly, resulting in a forecasted slowdown in earnings growth for this year and 2026 [5] - Earnings per share are projected to increase by only 3.8% this year and 4.8% in 2026, despite a 22% increase in 2024, with potential negative impacts from governmental pressure on GLP-1 prices [6][8] - Although Novo Nordisk appears cheap with a forward P/E ratio of 14 compared to Eli Lilly's 27, its valuation may not be justified given the growth outlook and potential price pressures [8]

Key Points New launches and label expansions should help Novo Nordisk maintain a strong position in its markets. Merck is planning for life after the Keytruda patent cliff thanks to new launches and a promising pipeline. 10 stocks we like better than Novo Nordisk › The market is forward-looking, but investors who earn better-than-average returns often look even further into the future and identify opportunities that are currently being overlooked. That means, among other things, buying shares of co ...